

28 April 2022

Actilyse® Cathflo® (alteplase) 2mg powder for solution for injection**- Temporary drug interruption in Ireland****Information for Physicians and Pharmacists**Reference: Metalyse (tenecteplase)
temporary drug interruption

Dear Sir/Madam

Boehringer Ingelheim (BI) would like to inform you about a temporary supply interruption of Actilyse® Cathflo® (alteplase) 2mg powder for solution for injection.

The Crescent Building, Northwood
Park,
Santry, Dublin 9,
D09 C6X8, Ireland
Telephone +353-1-2959620
Telefax +353-1-8163642
www.boehringer-ingelheim.ie

The estimated start of the supply interruption of Actilyse® Cathflo® (alteplase) 2mg in Ireland is from May 2022.

Currently the exact duration of the supply interruption for Actilyse® Cathflo® (alteplase) 2mg cannot be determined.

Based on our current assessment, we expect that the supply situation will remain constrained for the next two years. We will continue to update the HPRA with the current situation regarding availability.

Boehringer Ingelheim is committed to patient care and deeply regrets this situation.

Our team is continuously working towards a solution to restore stocks of Actilyse® Cathflo® (alteplase) 2mg to normal levels in the shortest possible time and minimize the impact on patients.

Should you require any further information please contact:

Page 2

For stock related enquiries - distribution.bra@boehringer-ingelheim.com;
+44 (0)1344 741101

For Medical enquiries, medinfo.bra@boehringer-ingelheim.com; +353 1
295 9620

Please distribute this information as you feel appropriate.

Yours faithfully



Uday Bose
Country Managing Director and Head of HP (UK and Ireland),
Boehringer Ingelheim